IMGN vs CLVS | IMGN Message Board Posts

ImmunoGen, Inc.

  IMGN website

  • Important Upgrade Notice: 

    At 9 pm Central, Sunday 2/16/2020, we launched the following tools as Phase One of our Premium Plus service (full service package still under development): 

    1) Customizable Scrolling Ticker
    2) Portfolio Manager
    3) Stock-specific News & Trading Email Alert Notifications

    These products are immediately available to Precious Metal & Gemstone Patrons. 

    To watch a tutorial on the "regular" site, click here. On "premium," click here

IMGN   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  49765 of 50354  at  8/13/2019 2:20:08 PM  by



Interesting to note that while we still do not have an approved product generating revenue we are valued more than Clovis that was a third entrant into the PARP inhibitor class which is forecasted to ring in $167M this year, posted $33M for Q2. Their market cap is $303M and $IMGN is $424M. So the promise of a first in class is better than a slow growing asset in a very competitive class of drugs. Really looking forward to what we learn at ESMO and if 632 data will be enough for special FDA consideration - fast track, breakthrough etc and to encourage Jazz to pull the trigger.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 0     Views: 297
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Msg # Subject Author Recs Date Posted
49766 Re: IMGN vs CLVS Bibliobiftek 1 8/13/2019 3:04:25 PM

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by